<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In order to improve the sensitivity of diagnosis of regional <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients, the novel molecular method called the one-step nucleic acid amplification (OSNA) assay using cytokeratin 19 mRNA as a molecular marker was developed </plain></SENT>
<SENT sid="1" pm="."><plain>In this method, the supernatant of a homogenized lymph node solution is directly analyzed without the <z:chebi fb="2" ids="33699">mRNA</z:chebi> purification process that is usually required in RT-PCR </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore the results are available within 30 min via a simple procedure, and the results correlate well with the number of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in the lymph node </plain></SENT>
<SENT sid="3" pm="."><plain>We conducted multicenter clinical trials in Japan to evaluate the OSNA assay for the detection of <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> in <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, and <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The results showed that the OSNA assay provides a judgment performance equivalent to that of 2-mm-interval histopathologic examinations of lymph nodes in each type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, the OSNA assay is unlikely to yield false-positives for histopathologically negative lymph nodes </plain></SENT>
<SENT sid="6" pm="."><plain>Following these results, the OSNA assay was approved as a diagnostic method for lymph node status in breast, colorectal, and <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> patients by the Japanese Ministry of Health, Labor and Welfare </plain></SENT>
<SENT sid="7" pm="."><plain>The OSNA assay is promising as a quick, simple, subjective, quantitative method for the detection of <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>